Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Large Decline in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 13,144 shares, a decline of 52.5% from the August 31st total of 27,645 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 422,623 shares, the short-interest ratio is presently 0.0 days.

Oncotelic Therapeutics Trading Down 8.9%

OTLC stock traded down $0.00 during mid-day trading on Thursday, reaching $0.02. 479,991 shares of the stock traded hands, compared to its average volume of 285,053. Oncotelic Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.11. The stock’s fifty day moving average is $0.03 and its 200-day moving average is $0.04. The company has a market cap of $9.77 million, a P/E ratio of 0.04 and a beta of -0.24. The company has a current ratio of 0.08, a quick ratio of 0.08 and a debt-to-equity ratio of 0.01.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel therapies for cancer and other serious diseases. The company’s research platform emphasizes RNA-based therapeutics and targets biological pathways involved in tumor growth, immune response, and disease progression.

Its principal investigational product is OT-101, also known as trabedersen, an antisense oligonucleotide designed to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has studied OT-101 in several oncology settings, including brain and other solid tumors.